Projects
- HPTN 107 (MAGI) — A Phase II randomized, observer-blind, placebo-controlled study, to assess efficacy of meningococcal Group B vaccine rMenB+OMV NZ (Bexsero) in preventing gonococcal infection (DMID Protocol No. 19-0004)
- HPTN 094 (Project RIDE) — INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care
- Purpose 2 — A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People ≥ 16Years of Age who Have Sex With Male Partners and are at Risk for HIV Infection
- HPTN 102 (Purpose 3)
- HVTN 142
- HVTN 144
- HVTN 807
- Moderna RSV
- HPTN 103 (Purpose 4)
Back to Top